Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Recursion Pharmaceuticals, Inc. Class A Common Stock

RXRX

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Last trade $2.63
Day change -$0.275 (-9.47%)
Day range $2.51 – $2.95
Volume 30,826,025
Market cap $1.81B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.81B
Price / earnings
—
Price / book
2×
Price / sales
26.59×
EV / sales
18.7×
EV / EBITDA
-3.03×

Profitability

Earnings per share
-$0.76
Return on assets
-38.93%
Return on equity
-52.51%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
5.01×
Quick ratio
5.01×
Cash ratio
4.47×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$312.48M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RXRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$18.55M$7.67M$6.47M$35.54M$5.18M$19.22M$14.75M$4.55M
Cost of revenue$10.05M$11.49M$12.49M$14.28M$14.69M$20.16M$21.83M$12.79M
Gross profit$8.51M-$3.82M-$6.02M$21.26M-$9.51M-$938K-$7.08M-$8.25M
Selling, general and administrative$32.56M$41.53M$34.59M$33.66M$41.63M$46.65M$54.65M$77.19M
Research and development$99.12M$89.61M$87.9M$95.94M$121.06M$128.64M$129.63M$98.33M
Total operating expenses$131.68M$131.15M$122.49M$129.6M$162.69M$175.29M$184.28M$175.52M
Operating income-$123.18M-$134.97M-$128.51M-$108.33M-$172.2M-$176.23M-$191.37M-$183.77M
Interest expense-$266K$0$0$0-$833K$0$0$0
Income before taxes-$119.01M-$131.01M-$122.11M-$108.1M-$162.25M-$171.9M-$202.65M-$178.9M
Income taxes$25K-$1K-$4.6M$20K$3K$0-$158K$7K
Net income-$119.04M-$131.01M-$117.5M-$108.12M-$162.25M-$171.9M-$202.49M-$178.91M
Net income attributable to common shareholders-$119.04M-$131.01M-$117.5M-$108.12M-$162.25M-$171.9M-$202.49M-$178.91M
EBITDA-$106.64M-$116.8M-$108.83M-$88.86M-$151.16M-$152.38M-$172.04M-$170.82M
Basic earnings per share-$0.22-$0.25-$0.22-$0.21-$0.36-$0.41-$0.50-$0.53
Diluted earnings per share-$0.22-$0.25-$0.22-$0.21-$0.36-$0.41-$0.50-$0.53

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.

GlobeNewswire Inc.

DaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnerships

DaltonTx announced the appointment of Melissa Landon, Ph.D., as Chief Commercial Officer to lead commercial strategy and expand adoption of its Dalton platform across pharma, biotech, and CRO partners. Landon brings 20+ years of AI/ML experience in drug discovery, most recently from Merck KGaA/MilliporeSigma, and previously served as Chief Strategy Officer at Cyclica.

Zacks Investment Research

RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway

Recursion Pharmaceuticals (RXRX) beat Q3 earnings and revenue estimates, reporting a narrower loss of $0.22 per share versus consensus of $0.24. The company highlighted encouraging Phase 2 data for REC-4881 in familial adenomatous polyposis with 87% of patients experiencing polyp burden reductions, and early oncology signals from REC-1245. With $748.7M in pro forma cash, management expects runway into 2029 and plans to initiate a registrational study for REC-4881 in H2 2027. Partnerships with Sanofi and Genentech continue to advance.

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

Recursion Pharmaceuticals reported a Q3 loss of $0.22 per share, beating the consensus estimate of $0.24 loss, with an 8.33% earnings surprise. Revenue of $18.55 million surpassed estimates by 69.88%, up from $5.18 million year-over-year. The stock has underperformed the S&P 500 by 12.2% year-to-date and carries a Zacks Rank #3 (Hold) rating.

The Motley Fool

1 Big Winner and 1 Loser From the Upcoming Anthropic IPO

Anthropic's upcoming IPO will have divergent impacts on companies in the AI and biotech sectors. Broadcom stands to benefit significantly from a $161.2 billion, five-year non-cancellable agreement to provide AI chip capacity to Anthropic. Conversely, Recursion Pharmaceuticals faces headwinds as Anthropic's Claude AI model becomes a standard tool for drug discovery among major pharmaceutical companies, eroding Recursion's competitive advantage despite the biotech having no approved drugs since its 2013 founding.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.